Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613787

— · D

13b5869b-5adb-58c7-a703-b4ccd84af27e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.730
  • INTERFERON_GAMMA_RESPONSE+0.710
  • ALLOGRAFT_REJECTION+0.630
  • IL6_JAK_STAT3_SIGNALING+0.470
  • INFLAMMATORY_RESPONSE+0.450
  • COMPLEMENT+0.430
  • IL2_STAT5_SIGNALING+0.310
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.190
  • APOPTOSIS+0.170
  • E2F_TARGETS+0.160

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.400
  • CHOLESTEROL_HOMEOSTASIS-0.390
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
  • MYOGENESIS-0.350
  • HEDGEHOG_SIGNALING-0.330
  • ESTROGEN_RESPONSE_LATE-0.320
  • ANGIOGENESIS-0.310
  • UV_RESPONSE_DN-0.300
  • ANDROGEN_RESPONSE-0.260
  • GLYCOLYSIS-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518190
breast-umap@18
—D0.937
2BSR_02_0049_A5_S69
breast-umap@18
—D0.921
3BSR_11_0107_E3_S77
breast-umap@18
—D0.898
4b03d2223-38c1-4bb3-be8b-27db05f87b66
melanoma-umap@29
——0.880
5SRR10842377
melanoma-umap@29
——0.879
6TCGA-EW-A1OV-01A-11R-A144-07
breast-umap@18
—D0.875
7SRR8613734
breast-umap@18
—D0.869
8TCGA-AR-A1AW-01A-21R-A12P-07
breast-umap@18
—D0.867
9SRR8518185
breast-umap@18
—D0.858
10TCGA-C8-A12V-01A-11R-A115-07
breast-umap@18
—D0.857

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.730Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.710Idelalisib— uncovered
ALLOGRAFT_REJECTION0.630Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.470Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.450Idelalisib— uncovered
COMPLEMENT0.430Inavolisib— uncovered
IL2_STAT5_SIGNALING0.310Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
APOPTOSIS0.170Idelalisib— uncovered
E2F_TARGETS0.160Inavolisib— uncovered
KRAS_SIGNALING_UP0.160Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.160Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.160Inavolisib— uncovered
UV_RESPONSE_UP0.120Idelalisib— uncovered
G2M_CHECKPOINT0.110Inavolisib— uncovered
MITOTIC_SPINDLE0.070Inavolisib— uncovered
PANCREAS_BETA_CELLS0.060Cobimetinib— uncovered
KRAS_SIGNALING_DN0.040Remibrutinib— uncovered
COAGULATION0.030Binimetinib— uncovered
HEME_METABOLISM0.030Temsirolimus— uncovered